World Health Organization. Global tuberculosis control 2011. Geneva: WHO Press, 2011. Available at http://www.who.int/entity/tb/publications/global_report/2011/gtbr11_full.pdf. (accessed 1 February 2012).
Google Scholar
Murray M, Oxlade O, Lin HH.Modeling social, environmental and biological determinants of tuberculosis. Int J Tuberc Lung Dis2011;15 Suppl 2:S64–S70.
PubMedGoogle Scholar
Lienhardt C.From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev2001;23:288–301.
PubMed Web of Science ®Google Scholar
Lawn SD, Churchyard G.Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS2009;4:325–333.
PubMed Web of Science ®Google Scholar
Raviglione MC, Snider DE Jr, Kochi A.Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA1995;273:220–226.
PubMed Web of Science ®Google Scholar
Getahun H, Gunneberg C, Granich R, Nunn P.HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis2010;50 Suppl 3:S201–S207.
PubMed Web of Science ®Google Scholar
Caminero JA.Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis2010;14:382–390.
PubMed Web of Science ®Google Scholar
Cox HS, McDermid C, Azevedo V et al.Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One2010;5:e13901.
PubMed Web of Science ®Google Scholar
Calver AD, Falmer AA, Murray M et al.Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis2010;16:264–271.
PubMed Web of Science ®Google Scholar
Zhao M, Li X, Xu P et al.Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One2009;4:e4370.
PubMed Web of Science ®Google Scholar
Nodieva A, Jansone I, Broka L, Pole I, Skenders G, Baumanis V.Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis2010;14:427–433.
PubMed Web of Science ®Google Scholar
The Stop TB Partnership and the World Health Organization. The Global Plan to Stop TB, 2011–2015. Geneva: WHO Press, 2010. Available at http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf. (accessed 30 January 2012).
Google Scholar
United Nations General Assembly. United Nations Millennium Declaration. 2000. Available at http://www.un.org/millennium/declaration/ares552e.pdf. (accessed 14 April 2012).
Google Scholar
The Stop TB Partnership and the World Health Organization. An International Roadmap for Tuberculosis Research.Geneva: WHO Press, 2011. Available at http://www.stoptb.org/assets/documents/resources/publications/technical/tbresearchroadmap.pdf. (accessed 14 April, 2012).
Google Scholar
The World Health Organization and the Stop TB Partnership. Priorities in operational research to improve tuberculosis care and control.Geneva: WHO Press, 2011. Available at http://www.who.int/tb/features_archive/operational_research_priorities/en/index.html. (accessed 1 February 2012).
Google Scholar
Policy Cures. G-FINDER 2011: neglected disease research and development.Sydney: Policy Cures, 2011. Available at http://policycures.org/publications.html. (accessed 2 March 2012).
Google Scholar
NIAID Tuberculosis Working Group. NIAID Research Agenda: multidrug-resistant and extensively drug-resistant tuberculosis.Bethesda: NIAID, 2007. Available at http://www.niaid.nih.gov/topics/tuberculosis/research/documents/mdrxdrresearchagenda.pdf. (accessed 30 March 2012).
Google Scholar
Bill and Melinda Gates Foundation Global Health Program. Strategy Overview: Tuberculosis. 2009. Available at http://www.gatesfoundation.org/global-health/Documents/tuberculosis-strategy.pdf. (accessed 2 May 2012).
Google Scholar
Brennan MJ, Thole J.Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis2012;92 Suppl 1:S6–S13.
PubMed Web of Science ®Google Scholar
Daniel TM.The history of tuberculosis. Respir Med2006;100:1862–1870.
PubMed Web of Science ®Google Scholar
Abu-Raddad LJ, Sabatelli L, Achterberg JT et al.Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A2009;106:13980–13985.
PubMed Web of Science ®Google Scholar
Lonnroth K, Raviglione M.Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med2008;29:481–491.
PubMed Web of Science ®Google Scholar
Russell DG, Barry CE 3rd, Flynn JL.Tuberculosis: what we don't know can, and does, hurt us. Science2010;328:852–856.
PubMed Web of Science ®Google Scholar
Global Alliance for TB Drug Development.Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb)2001;81 Suppl 1:S1–S52.
PubMed Web of Science ®Google Scholar
Walker KB, Brennan MJ, Ho MM et al.The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine2010;28: 2259–2270.
PubMedGoogle Scholar
The New Diagnostics Working Group of the Stop TB Partnership. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics.Geneva: WHO Press, 2009. Available at http://whqlibdoc.who.int/publications/2009/9789241598811_eng.pdf. (accessed 22 January 2012).
Google Scholar
Vynnycky E, Fine PE.The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect1997;119:183–201.
PubMed Web of Science ®Google Scholar
Lawn SD, Wood R, Wilkinson RJ.Changing concepts of ‘latent tuberculosis infection’ in patients living with HIV infection. Clin Dev Immunol2011;2011 pii: 980594.
PubMedGoogle Scholar
Achkar JM, Jenny-Avital ER.Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis2011;204 Suppl 4:S1179–S1186.
PubMed Web of Science ®Google Scholar
Esmail H, Barry CE 3rd, Wilkinson RJ.Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today2012;17:514–521.
PubMed Web of Science ®Google Scholar
Rangaka MX, Wilkinson KA, Glynn JR et al.Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis2012;12:45–55.
PubMed Web of Science ®Google Scholar
Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D.Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis2011;15:1018–1032.
PubMed Web of Science ®Google Scholar
Diel R, Loddenkemper R, Nienhaus A.Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest2012 Apr 5; https://doi.org/10.1378/chest.11-3157 doi:10.1378/chest.11-3157.
Google Scholar
Gideon HP, Flynn JL.Latent tuberculosis: what the host ‘sees’? Immunol Res2011;50:202–212.
PubMed Web of Science ®Google Scholar
Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A.Immunological biomarkers of tuberculosis. Nat Rev Immunol2011;11:343–354.
PubMed Web of Science ®Google Scholar
Ottenhoff TH, Ellner JJ, Kaufmann SH.Ten challenges for TB biomarkers. Tuberculosis (Edinb)2012;92 Suppl 1:S17–S20.
PubMed Web of Science ®Google Scholar
Berry MP, Graham CM, McNab FW et al.An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature2010;466:973–977.
PubMed Web of Science ®Google Scholar
Menzies D, Al Jahdali H, Al Otaibi B.Recent developments in treatment of latent tuberculosis infection. Indian J Med Res2011;133:257–266.
PubMed Web of Science ®Google Scholar
Ehlers S.Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection2009;37:87–95.
PubMed Web of Science ®Google Scholar
Trunz BB, Fine P, Dye C.Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet2006;367:1173–1180.
PubMed Web of Science ®Google Scholar
Randhawa AK, Shey MS, Keyser A et al.Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS Pathog2011;7:e1002174.
PubMed Web of Science ®Google Scholar
Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N.Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev2008;32:821–841.
PubMed Web of Science ®Google Scholar
Brennan MJ, Clagett B, Fitzgerald H et al.Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine2012;30:2811–2823.
PubMed Web of Science ®Google Scholar
Critical path to TB drug regimens.2012.Available at http://cptrinitiative.org/ (accessed 1 June 2012).
Google Scholar
Blumberg HM, Burman WJ, Chaisson RE et al.American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med2003;167:603–662.
PubMed Web of Science ®Google Scholar
World Health Organization. Guidelines for programmatic management of drug-resistant tuberculosis.Geneva: WHO Press, 2011. Available at http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf. (accessed 14 February 2012).
Google Scholar
Shah NS, Wright A, Bai GH et al.Worldwide emergence of extensively drug-resistant tuberculosis. Emerging infectious diseases2007;13:380–387.
PubMed Web of Science ®Google Scholar
McDermott W.Microbial persistence. Yale J Biol Med1958;30:257–291.
PubMedGoogle Scholar
Fauvart M, de Groote VN, Michiels J.Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol2011;60(Pt 6): 699–709.
PubMed Web of Science ®Google Scholar
Zhang Y, Yew WW, Barer MR.Targeting persisters for tuberculosis control. Antimicrob Agents Chemother2012;56:2223–2230.
PubMed Web of Science ®Google Scholar
Mitchison DA.The search for new sterilizing anti-tuberculosis drugs. Front Biosci2004;9:1059–1072.
PubMed Web of Science ®Google Scholar
Yasinskaya Y, Sacks L.Models and approaches for anti-TB drug testing. Expert Rev Anti Infect Ther2011;9:823–831.
PubMed Web of Science ®Google Scholar
Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X.Global tuberculosis drug development pipeline: the need and the reality. Lancet2010;375:2100–2109.
PubMed Web of Science ®Google Scholar
Miyata T, Cheigh CI, Casali N et al.An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis. Vaccine2012;30:459–465.
PubMed Web of Science ®Google Scholar
Van Deun A, Salim MA, Das AP, Bastian I, Portaels F.Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis2004;8:560–567.
PubMed Web of Science ®Google Scholar
National Institute of Allergy and Infectious Diseases. Restructuring the NIAID Clinical Trials Networks.Bethesda: National Institute of Allergy and Infectious Diseases; 2012. Available at http://www.niaid.nih.gov/labsandresources/restructuring (accessed 14 February 2012).
Google Scholar
National Institute of Allergy and Infectious Diseases. Resources for researchers.Bethesda: National Institute of Allergy and Infectious Diseases; 2012. Available at http://www.niaid.nih.gov/labsandresources/resources (accessed 1 June 2012).
Google Scholar
Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH.Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun2004;72:1065–1071.
PubMed Web of Science ®Google Scholar
McCune RM, Feldmann FM, Lambert HP, McDermott W.Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med1966;123:445–468.
PubMed Web of Science ®Google Scholar
McCune RM, Feldmann FM, McDermott W.Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med1966;123:469–486.
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The role of biomedical research in global tuberculosis control: gaps and challenges

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature